医薬品添加剤市場- 世界の産業規模、シェア、動向、機会、予測、製品別、機能別、剤形別、地域別、競合別、2020～2030年

医薬品添加剤の世界市場規模は2024年に85億2,000万米ドル、予測期間中のCAGRは5.25%で2030年には114億5,000万米ドルに達すると予測されています。

製薬業界は、研究、テクノロジーの進歩、革新的なヘルスケアソリューションに対する需要の高まりによって、ダイナミックに進化し続けるセクターです。この複雑な状況の中で、情勢は医薬品有効成分（API）の製剤化と送達を助ける不活性物質として重要な役割を果たしています。世界の医薬品添加剤市場は著しい成長と変貌を遂げ、安全で効果的な医薬品の開発に不可欠な要素となっています。研究開発活動の活発化により拡大する製薬業界が、賦形剤市場の1次促進要因となっています。製薬会社は新しい製剤を市場に投入しようと努力しているため、薬物の安定性、溶解性、バイオアベイラビリティを高める賦形剤の需要が著しく高まっています。

徐放性製剤、標的薬物送達システム、ナノテクノロジーなど、ドラッグデリバリーにおける技術革新は、特定の機能性を持つ賦形剤に対する需要を生み出しています。賦形剤は、標的とする組織や臓器に薬剤を正確に送達し、治療成績を向上させる上で極めて重要な役割を果たしています。患者のコンプライアンスと利便性が重視される中、患者に優しい剤形を開発する傾向が高まっています。賦形剤は、口腔内崩壊錠、液剤、その他の患者中心の剤形の製剤化を可能にし、服薬アドヒアランスの向上に貢献します。世界中の規制機関は、医薬品の品質、安全性、有効性を重視しています。規制基準やガイドラインに準拠した賦形剤の採用が増加しており、市場をさらに牽引しています。

主な市場促進要因

革新的な製剤に対する需要の高まり

医薬品研究開発投資の増加

主な市場課題

コスト圧力

主な市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の医薬品添加剤市場に与える影響

第5章 世界の医薬品添加剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（有機化学品、油脂化学品（脂肪アルコール、金属ステアリン酸塩、グリセリン、その他）、炭水化物（糖類、アルコール、デンプン）、石油化学製品、タンパク質、リン酸カルシウム、金属酸化物、岩塩、炭酸カルシウム、硫酸カルシウム、その他）
  • 機能別（充填剤および希釈剤、懸濁剤および粘稠剤、コーティング剤、結合剤、香味剤および甘味料、崩壊剤、着色剤、潤滑剤および流動化剤、保存料、乳化剤、その他）
  • 剤形別（経口剤、錠剤、カプセル剤（ハードゼラチンカプセル、ソフトゼラチンカプセル）、液剤、局所用剤、非経口剤、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の医薬品添加剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 機能別
  • 処方別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の医薬品添加剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 機能別
  • 処方別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の医薬品添加剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 機能別
  • 処方別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の医薬品添加剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 機能別
  • 処方別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの医薬品添加剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 機能別
  • 処方別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • UAEの医薬品添加剤市場展望
    • 市場規模・予測
      • 金額別
    • 市場シェア・予測
      • 製品別
      • 機能別
      • 処方別

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の医薬品添加剤市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• BASF SE
• Origin Instruments Corporation
• Ashland Global Holdings
• DuPont de Nemours, Inc.
• Roquette Feres
• Evonik Industries AG
• Associated British Foods
• Archer Daniels Midland Company
• Lubrizol Corporation
• Croda International
• Kerry Group

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Pharmaceutical Excipients Market was valued at USD 8.52 Billion in 2024 and is expected to reach USD 11.45 Billion by 2030 with a CAGR of 5.25% during the forecast period. The pharmaceutical industry is a dynamic and ever-evolving sector, driven by advancements in research, technology, and an increasing demand for innovative healthcare solutions. Within this intricate landscape, pharmaceutical excipients play a crucial role as inert substances that aid in the formulation and delivery of active pharmaceutical ingredients (APIs). The global pharmaceutical excipients market has witnessed significant growth and transformation, becoming a vital component in the development of safe and effective pharmaceutical products. The expanding pharmaceutical industry, fueled by increased research and development activities, is a primary driver of the excipients market. As pharmaceutical companies strive to bring novel drug formulations to market, the demand for excipients that enhance drug stability, solubility, and bioavailability has risen significantly.

Technological innovations in drug delivery, including sustained-release formulations, targeted drug delivery systems, and nanotechnology, have created a demand for excipients with specific functionalities. Excipients play a pivotal role in ensuring the precise delivery of drugs to targeted tissues or organs, thereby improving therapeutic outcomes. With a focus on patient compliance and convenience, there is a growing trend toward the development of patient-friendly dosage forms. Excipients enable the formulation of orally disintegrating tablets, liquid formulations, and other patient-centric dosage forms, contributing to improved medication adherence. Regulatory bodies worldwide are emphasizing the importance of quality, safety, and efficacy in pharmaceutical products. Excipients that comply with regulatory standards and guidelines are witnessing increased adoption, driving the market further.

Key Market Drivers

Rising Demand for Innovative Drug Formulations

The global pharmaceutical industry is undergoing a transformative phase, driven by advancements in medical science and an increasing focus on patient-centric healthcare solutions. One of the key elements contributing to this evolution is the rising demand for innovative drug formulations. As pharmaceutical companies strive to develop more effective and patient-friendly medications, the role of pharmaceutical excipients has come into sharp focus. Pharmaceutical excipients are inactive substances that play a crucial role in drug formulation. While active pharmaceutical ingredients (APIs) are responsible for the therapeutic effects of a drug, excipients serve various functions, such as enhancing stability, improving bioavailability, and ensuring the proper release of the active ingredient. The pharmaceutical excipients market has witnessed significant growth in recent years, driven by the need for novel drug delivery systems and formulations that address the challenges of traditional drug development.

As the pharmaceutical industry continues to prioritize safer, more effective medicines, there is an increasing need for excipients that can support complex formulations and enhance drug delivery systems. Clariant unveiled a new line of high-performance excipients at the CPHI Milan 2024 trade show in October. This new portfolio, comprising eight advanced products, aims to enhance the development of safe and effective medicines. The expanded product range includes excipients tailored for diverse applications, such as those designed for sensitive active pharmaceutical ingredients (APIs), parenteral formulations, and situations where the final product must remain colorless. Among the new introductions are VitiPure LEX 3350 S, VitiPure LEX 4000 S, and Polyglykol 1450 S excipients crafted to address challenges related to API delivery and bioavailability. Specifically, the VitiPure LEX line is optimized for formulations requiring precise control over microbial load, making these co-solvents ideal for sensitive applications and APIs, including those with low water solubility. These innovations directly contribute to market growth by addressing the evolving needs of pharmaceutical manufacturers. The ability to control microbial load in formulations and enhance the stability of sensitive APIs opens up opportunities for creating more effective therapies, particularly in areas like parenteral formulations and precision medicine.

The pharmaceutical industry is increasingly moving toward novel drug delivery systems to enhance the efficacy and safety of medications. Excipients play a pivotal role in these systems, contributing to controlled-release formulations, targeted drug delivery, and improved bioavailability. Advanced technologies, such as nanotechnology and microencapsulation, rely heavily on specialized excipients to achieve precise drug delivery. The evolving healthcare landscape emphasizes patient-centric approaches, with a focus on personalized medicine. This shift has led to a growing demand for formulations that are easy to administer, have improved taste and texture, and ensure patient compliance. Excipients contribute to the development of patient-friendly dosage forms, such as orally disintegrating tablets, liquid formulations, and modified-release capsules. Regulatory bodies worldwide are increasingly emphasizing the quality and safety of pharmaceutical products. Excipients, as crucial components of drug formulations, are subject to rigorous regulatory scrutiny. Manufacturers are compelled to adhere to strict quality standards, driving innovation in excipient development to meet regulatory requirements and ensure the safety and efficacy of pharmaceutical products. The rise of biopharmaceuticals and biosimilars has presented unique challenges in terms of formulation and stability. Excipients are vital in stabilizing these complex molecules, maintaining their structural integrity, and ensuring proper delivery. The growing market for biopharmaceuticals has consequently fueled the demand for excipients designed to meet the specific needs of these advanced therapeutic modalities. Pharmaceutical companies are investing heavily in research and development to discover new and more effective treatments. This includes the exploration of innovative excipients to overcome formulation challenges, improve drug performance, and optimize the overall drug development process.

Increasing Pharmaceutical R&D Investments

The global pharmaceutical industry is experiencing a transformative phase driven by advancements in research and development (R&D). One significant contributor to this evolution is the growing focus on pharmaceutical excipients - the inert substances used as carriers or vehicles for active pharmaceutical ingredients (APIs). As pharmaceutical companies strive to enhance drug delivery systems and improve overall product efficacy, the demand for innovative excipients has surged. This surge is closely linked to the substantial increase in R&D investments across the pharmaceutical sector. Pharmaceutical research and development represent the cornerstone of medical progress. In recent years, there has been a notable uptick in R&D investments by pharmaceutical companies globally. Factors such as the need to address complex diseases, the pursuit of personalized medicine, and the exploration of novel therapeutic modalities have spurred an era of unprecedented innovation. One key driver of increased R&D spending is the rising prevalence of chronic diseases, necessitating the development of targeted and efficient drug delivery systems. Additionally, the global population is aging, leading to a growing demand for innovative pharmaceutical solutions that cater to the specific needs of elderly patients. As pharmaceutical companies aim to bring novel and effective drugs to market, the importance of excipients in optimizing drug formulations has become more evident.

Excipients play a crucial role in drug formulation by ensuring the stability, bioavailability, and controlled release of active pharmaceutical ingredients. They serve as essential components in various dosage forms, including tablets, capsules, injections, and topical formulations. Excipients contribute to the overall safety and effectiveness of pharmaceutical products, influencing factors such as drug solubility, absorption, and stability. In recent years, there has been a paradigm shift in the perception of excipients from mere inert substances to active contributors in drug development. Excipients are now recognized for their ability to enhance drug performance, improve patient compliance, and facilitate the development of specialized drug delivery systems. The rise in pharmaceutical R&D investments is significantly fueling growth in the global pharmaceutical excipients market. In 2023, the research-based pharmaceutical industry invested approximately USD 52.07 billion in R&D across Europe, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA). This surge in investment reflects the industry's commitment to advancing drug development and innovation. Notably, China has surpassed Europe as the leader in introducing new active substances to the global market, with 25 new substances launched compared to Europe's 17. However, the United States continues to lead globally, with 28 new substances out of a total of 90 worldwide. This increasing focus on R&D not only accelerates the development of new drugs but also drives demand for advanced pharmaceutical excipients, which play a crucial role in optimizing drug formulations and improving bioavailability. The heightened investment in R&D underscores the growing need for innovative excipients to support the evolving pharmaceutical landscape and contribute to the continued growth of the excipients market.

The increasing emphasis on excipient innovation has propelled the global pharmaceutical excipients market to new heights. According to industry reports, the market is experiencing robust growth, with projections indicating sustained expansion in the coming years. The surge in pharmaceutical R&D investments has created a fertile ground for excipient manufacturers to develop and introduce cutting-edge products that meet the evolving needs of drug developers. Moreover, the pharmaceutical excipients market is witnessing a shift towards multifunctional excipients that can address multiple formulation challenges simultaneously. Excipients that enhance drug solubility, improve bioavailability, and enable controlled release are particularly in high demand. As pharmaceutical companies continue to explore biologics, personalized medicine, and other advanced therapeutic areas, the demand for specialized excipients tailored to these applications is expected to grow.

Key Market Challenges

Cost Pressures

The global pharmaceutical excipients market plays a pivotal role in the development and production of pharmaceutical formulations. Excipients, often overlooked by consumers, are crucial components that contribute to the stability, bioavailability, and overall efficacy of pharmaceutical products. While the industry is witnessing significant growth, it is not without its challenges. One of the most pressing issues is the relentless cost pressures that pharmaceutical excipient manufacturers face. The primary raw materials used in the production of pharmaceutical excipients include cellulose, starch, sugars, and polymers. Fluctuations in the prices of these raw materials can significantly impact production costs. External factors such as geopolitical events, climate change, and market dynamics can lead to unpredictable and sudden increases in raw material prices.

The pharmaceutical industry is heavily regulated, and excipient manufacturers must comply with strict quality standards and regulatory requirements. Achieving and maintaining compliance often involves substantial investments in research, development, and quality control processes, contributing to increased operational costs. The pharmaceutical industry is rapidly evolving, with continuous advancements in manufacturing technologies. While these innovations can lead to improved efficiency and product quality, they also necessitate substantial investments in equipment, training, and infrastructure, adding to the financial burden on manufacturers. Economic conditions, both globally and regionally, play a crucial role in shaping the cost landscape for pharmaceutical excipient manufacturers. Economic downturns, currency fluctuations, and geopolitical uncertainties can create an unpredictable business environment, making financial planning and cost containment challenging.

Key Market Trends

Technological Advancements

The global pharmaceutical industry is undergoing a transformative phase, driven by rapid technological advancements. One of the key beneficiaries of this progress is the pharmaceutical excipients market, which plays a crucial role in drug formulation and delivery. Pharmaceutical excipients are inert substances added to pharmaceutical formulations to enhance their stability, bioavailability, and overall efficacy. As technology continues to evolve, the pharmaceutical excipients market is experiencing significant growth, offering novel opportunities for innovation and efficiency. The formulation of pharmaceuticals has witnessed a paradigm shift with the integration of advanced technologies. Nanotechnology, for example, has opened new avenues for drug delivery systems. Nano-sized excipients enable improved solubility and targeted drug delivery, enhancing the overall therapeutic effect. This has led to the development of more effective and patient-friendly drug formulations. Moreover, the application of 3D printing technology in pharmaceuticals is gaining momentum. This technology allows for the precise deposition of pharmaceutical excipients and active ingredients layer by layer, facilitating the creation of personalized medicines with specific release profiles. The ability to customize drug formulations based on individual patient needs is a significant advancement that is reshaping the pharmaceutical landscape. Quality by Design (QbD) approaches, facilitated by advanced analytical tools and software, are becoming integral to the formulation process. QbD emphasizes the systematic development of pharmaceutical products to ensure quality and performance, thereby reducing the need for post-approval changes. This approach not only accelerates the drug development process but also enhances the reliability of pharmaceutical formulations.

In October 2024, Curapath and Certest Biotech formed a strategic partnership through a collaboration and licensing agreement to introduce groundbreaking lipid nanoparticle (LNP) formulations. By combining Certest's proprietary ionizable lipids with Curapath's shielding lipids, this collaboration is set to offer the market advanced solutions that will help biotech and pharmaceutical companies develop more precise, efficient, and safer treatments. These formulations are particularly targeted at high-demand areas like vaccines for infectious diseases, gene therapy, and immuno-oncology. Additionally, the partnership aims to reduce intellectual property barriers, making these innovations more accessible to the broader industry. This collaboration underscores the significant role technological advancements play in driving the growth of the pharmaceutical excipients market. As the demand for more specialized and effective drug delivery systems increases, such innovations are key to developing next-generation therapies. This strategic partnership is a clear example of how technological progress in drug formulation is helping to meet evolving market needs, further fueling growth in the global pharmaceutical excipients sector.

Technological advancements have enabled the development of excipients that enhance drug stability and bioavailability. Excipients with controlled release properties help maintain optimal drug concentrations in the body, prolonging therapeutic effects and reducing the frequency of dosing. This is particularly crucial for patients with chronic conditions, improving treatment adherence and overall patient outcomes. Innovations in polymer science have led to the creation of biocompatible and biodegradable excipients that can be tailored for sustained-release formulations. These advancements contribute to the development of long-acting medications, offering patients the convenience of less frequent dosing while maintaining therapeutic efficacy. The pharmaceutical excipients market is not only influenced by advancements in formulation technologies but also by innovations in digitalization and supply chain management. The integration of digital platforms and analytics tools helps streamline the production process, optimize resource allocation, and ensure consistent product quality. Real-time monitoring and data analytics enable manufacturers to identify and address potential issues in the production line promptly. This contributes to the overall efficiency of pharmaceutical excipient manufacturing, reducing waste and ensuring a reliable supply of high-quality excipients.

Segmental Insights

Product Insights

Based on product, the Organic Chemicals emerged as the fastest growing segment in the global market for Pharmaceutical Excipients during the forecast period Organic chemicals, including polymers, binders, and stabilizers, are vital to enhancing the performance of drug formulations by ensuring stability, bioavailability, and controlled release of active pharmaceutical ingredients (APIs). With the rising demand for more advanced drug delivery systems, organic chemicals are instrumental in refining these formulations to achieve optimal therapeutic outcomes. They provide flexibility for customization across various treatment types, such as using specific polymers and sugars to adjust drug release rates or improve solubility for poorly soluble compounds. This versatility makes them indispensable for the increasing shift toward targeted and controlled-release medications. For example, in May 2024, Roquette introduced its LYCAGEL Flex hydroxypropyl pea starch premix for nutraceutical and pharmaceutical softgel capsules. Built on Roquette's LYCAGEL pea starch technology, this new plasticizer-free excipient allows manufacturers to select the best plasticizer combinations, offering greater flexibility in formulation customization to meet a wide range of production and consumer requirements.

Organic chemicals are often derived from renewable resources, which aligns with the growing focus on sustainability within the pharmaceutical industry. Many of these excipients are biocompatible and biodegradable, making them particularly suitable for drug formulations, especially in parenteral and injectable products. Furthermore, organic excipients are widely favored in the industry due to their well-established safety profiles and regulatory approvals, making them the preferred choice for developing new drugs that must meet rigorous regulatory standards. As demand for generic and complex generic drugs increases, organic chemicals play a crucial role in formulating cost-effective, high-quality products that can compete with branded drugs. The use of organic excipients enables manufacturers to create formulations that are both effective and affordable. Ultimately, the combination of performance benefits, adaptability, regulatory compliance, and sustainability is driving the rapid growth of organic chemicals in the pharmaceutical excipients market.

Formulations Insights

Based on Formulation, the oral formulations emerged as the dominating segment in the global market for Pharmaceutical Excipients in 2024. Oral dosage forms, including tablets and capsules, are the most widely prescribed and consumed medications globally. They are preferred for their ease of administration, strong patient acceptance, and convenience. Patients tend to favor oral medications over alternatives like injections or topical treatments due to their simplicity and comfort. Additionally, oral formulations are more cost-effective to manufacture compared to parenteral or other specialized drug delivery methods. The standardized production processes for tablets and capsules allow for large-scale, cost-efficient manufacturing, ultimately lowering overall healthcare costs. This makes oral medications an attractive option for both generic and branded drug producers. Oral formulations offer significant flexibility in their design, allowing pharmaceutical companies to develop various types of tablets and capsules tailored to diverse therapeutic needs. Recent advancements in drug delivery systems, such as controlled-release tablets and capsules, have further enhanced their effectiveness by improving bioavailability and the controlled release of active ingredients. These innovations have expanded the range of drugs that can be effectively delivered orally, boosting the market share of oral formulations.

Oral medications are used to treat a wide range of conditions, from chronic diseases like diabetes and hypertension to acute conditions like infections and pain. Their versatility, coupled with the ability to deliver both small-molecule drugs and newer biologics in oral form, continues to drive their widespread use in the pharmaceutical industry. The increasing prevalence of generic drugs, predominantly produced in tablet or capsule form, has also reinforced the dominance of oral formulations. Generic medications provide substantial cost savings while offering the same therapeutic benefits as branded alternatives, further driving the demand for excipients used in oral formulations. With ongoing advancements in drug delivery technologies and a continued preference for oral treatments, oral formulations are expected to maintain their leading position in the pharmaceutical excipients market.

Regional Insights

Based on Region, North America emerged as the dominant region in the Global Pharmaceutical Excipients Market in 2024. North America, particularly the United States, hosts some of the world's largest pharmaceutical companies, such as Pfizer, Merck, Johnson & Johnson, and Abbott. These industry leaders drive substantial demand for pharmaceutical excipients, essential components in drug formulations. The region's strong and well-funded pharmaceutical R&D sector further accelerates the need for high-quality excipients. North America also represents a major market for generic drugs, which commonly rely on excipients in oral forms like tablets and capsules. With rising healthcare costs, both patients and healthcare providers are increasingly turning to generics. According to the Office of Generic Drugs' 2022 Annual Report, approximately 91% of all prescriptions in the U.S. are filled with generic drugs, with over 32,000 generics approved by the FDA. This growing preference for generics directly drives demand for excipients in these cost-effective formulations. Furthermore, North America is the largest consumer of pharmaceutical excipients, fueled by its significant pharmaceutical manufacturing base and large population. The aging population and the rising prevalence of chronic diseases further contribute to the growing demand for pharmaceuticals, and, consequently, the excipient market.

Key Market Players

• BASF SE
• Origin Instruments Corporation
• Ashland Global Holdings
• DuPont de Nemours, Inc.
• Roquette Feres
• Evonik Industries AG
• Associated British Foods
• Archer Daniels Midland Company
• Lubrizol Corporation
• Croda International
• Kerry Group

Report Scope:

In this report, the Global Pharmaceutical Excipients Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Excipients Market, By Product:

• Organic Chemicals
• Oleochemicals (Fatty Alcohols, Metal Stearates, Glycerin, Other)
• Carbohydrates (Sugars, Alcohol, Starches)
• Petrochemicals
• Proteins
• Calcium Phosphate
• Metal Oxides
• Halites
• Calcium Carbonate
• Calcium Sulphate
• Others

Pharmaceutical Excipients Market, By Formulation:

• Oral Formulations
• Tablets
• Capsules(Hard-gelatin Capsules, Soft-gelatin Capsules)
• Liquid Formulations
• Topical Formulations
• Parenteral Formulations
• Other

Pharmaceutical Excipients Market, By Functionality:

• Fillers & Diluents
• Suspending & Viscosity Agents
• Coating Agents
• Binders
• Flavoring Agents & Sweeteners
• Disintegrants
• Colorants
• Lubricants & Glidants
• Preservatives
• Emulsifying Agents
• Others

Pharmaceutical Excipients Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Pharmaceutical Excipients Market.

Available Customizations:

Global Pharmaceutical Excipients market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Pharmaceutical Excipients Market

5. Global Pharmaceutical Excipients Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Organic Chemicals, Oleochemicals (Fatty Alcohols, Metal Stearates, Glycerin, Other), Carbohydrates (Sugars, Alcohol, Starches), Petrochemicals, Proteins, Calcium Phosphate, Metal Oxides, Halites, Calcium Carbonate, Calcium Sulphate, Others)
  • 5.2.2. By Functionality (Fillers & Diluents, Suspending & Viscosity Agents, Coating Agents, Binders, Flavoring Agents & Sweeteners, Disintegrants, Colorants, Lubricants & Glidants, Preservatives, Emulsifying Agents, Others)
  • 5.2.3. By Formulation (Oral Formulations, Tablets, Capsules (Hard-gelatin Capsules, Soft-gelatin Capsules), Liquid Formulations, Topical Formulations, Parenteral Formulations, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Pharmaceutical Excipients Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Functionality
  • 6.2.3. By Formulation
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Pharmaceutical Excipients Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Functionality
      • 6.3.1.2.3. By Formulation
  • 6.3.2. India Pharmaceutical Excipients Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Functionality
      • 6.3.2.2.3. By Formulation
  • 6.3.3. Australia Pharmaceutical Excipients Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Functionality
      • 6.3.3.2.3. By Formulation
  • 6.3.4. Japan Pharmaceutical Excipients Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product
      • 6.3.4.2.2. By Functionality
      • 6.3.4.2.3. By Formulation
  • 6.3.5. South Korea Pharmaceutical Excipients Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product
      • 6.3.5.2.2. By Functionality
      • 6.3.5.2.3. By Formulation

7. Europe Pharmaceutical Excipients Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Functionality
  • 7.2.3. By Formulation
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pharmaceutical Excipients Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Functionality
      • 7.3.1.2.3. By Formulation
  • 7.3.2. Germany Pharmaceutical Excipients Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Functionality
      • 7.3.2.2.3. By Formulation
  • 7.3.3. Spain Pharmaceutical Excipients Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Functionality
      • 7.3.3.2.3. By Formulation
  • 7.3.4. Italy Pharmaceutical Excipients Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Functionality
      • 7.3.4.2.3. By Formulation
  • 7.3.5. United Kingdom Pharmaceutical Excipients Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Functionality
      • 7.3.5.2.3. By Formulation

8. North America Pharmaceutical Excipients Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Functionality
  • 8.2.3. By Formulation
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Pharmaceutical Excipients Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Functionality
      • 8.3.1.2.3. By Formulation
  • 8.3.2. Mexico Pharmaceutical Excipients Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Functionality
      • 8.3.2.2.3. By Formulation
  • 8.3.3. Canada Pharmaceutical Excipients Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Functionality
      • 8.3.3.2.3. By Formulation

9. South America Pharmaceutical Excipients Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Functionality
  • 9.2.3. By Formulation
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pharmaceutical Excipients Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Functionality
      • 9.3.1.2.3. By Formulation
  • 9.3.2. Argentina Pharmaceutical Excipients Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Functionality
      • 9.3.2.2.3. By Formulation
  • 9.3.3. Colombia Pharmaceutical Excipients Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Functionality
      • 9.3.3.2.3. By Formulation

10. Middle East and Africa Pharmaceutical Excipients Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Functionality
  • 10.2.3. By Formulation
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pharmaceutical Excipients Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Functionality
      • 10.3.1.2.3. By Formulation
  • 10.3.2. Saudi Arabia Pharmaceutical Excipients Market Outlook
    • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Functionality
      • 10.3.2.2.3. By Formulation
  • 10.3.3. UAE Pharmaceutical Excipients Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Functionality
      • 10.3.3.2.3. By Formulation

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Pharmaceutical Excipients Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. BASF SE
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
• 15.2. Origin Instruments Corporation
• 15.3. Ashland Global Holdings
• 15.4. DuPont de Nemours, Inc.
• 15.5. Roquette Feres
• 15.6. Evonik Industries AG
• 15.7. Associated British Foods
• 15.8. Archer Daniels Midland Company
• 15.9. Lubrizol Corporation
• 15.10. Croda International
• 15.11. Kerry Group

16. Strategic Recommendations

17. About Us & Disclaimer